Strategies such as gradual drug titration, understanding drugtarget interactions for repurposing, system-wide approaches in drug development, optimized dosing, and improved drug delivery systems are all aimed at reducing these side effects [19]
Compared with group C, the levels of PO 2 and Cl were increased in group D, and the difference was statistically significant
Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)
If you suspect you've experienced a side effect from either medication, report it through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)